Arrivent Biopharma Inc (AVBP) Stock Price, Quote & News

Company Profile

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment o...

Industry: Biotechnology

Sector: Healthcare

Phone: 628 277 4836

Website: arrivent.com

Address:

18 Campus Boulevard, Suite 100, Newtown Square, United States

StockNews_Live Mar. 17 at 9:01 PM

$AVBP 🎯 STOCK NEWS ALERT 💵 Price: $24.03 (-1.23%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Aarvik Therapeutics will present two posters and a minisymposium talk at the AACR Annual Meeting 2026. The presentations display the breadth of Aarvik’s capabilities in the ADC space. Aarvik, along… 📎 https://stocknews.live/news/AVBP/aarvik-therapeutics-showcases-novel-adc-molecules-based-on-muttatm-fxmofbpxue4r.html

0 · Reply

OfficialStocktwitsUser Mar. 16 at 4:29 PM

$AVBP RSI: 56.38, MACD: 0.5568 Vol: 1.00, MA20: 23.91, MA50: 22.64 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Stackdoe101 Mar. 9 at 2:43 PM

$AVBP $OMDA $RDNW $AVXL 🙃✨

0 · Reply

elmono Mar. 6 at 10:01 AM

$AVBP event driven data delayed to mid 2026 is likely a positive for trial outcome….. if anything the balance of probabilities should cause the sp to rise …..

1 · Reply

Eagley3k Mar. 6 at 1:02 AM

$AVBP data delayed to mid 2026?

2 · Reply

StockNews_Live Mar. 5 at 9:05 PM

$AVBP ArriVent BioPharma, Inc. reported financial results for the year ended December 31, 2025, and highlighted recent company progress. The company is advancing firmonertinib toward potential registration,…

0 · Reply

justiceforb_85 Mar. 5 at 2:17 AM

$AVBP impressive movement.

0 · Reply

judgeyoung2 Mar. 4 at 6:11 PM

$AVBP i guess i’ll strangle it. if no data comes by tomorrow, i’ll dip.

0 · Reply

judgeyoung2 Mar. 4 at 4:17 PM

$AVBP @cubie @tonyctl anything interesting on the flow?

1 · Reply

Zawang Mar. 4 at 3:54 PM

$AVBP why is this up so much today? I can’t find any news.

0 · Reply

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

Mar 5, 2026, 4:01 PM EST - 12 days ago

ArriVent BioPharma Reports Full Year 2025 Financial Results

Jan 4, 2026, 3:26 AM EST - 2 months ago

ArriVent BioPharma: Its Leading Asset Furmonertinib Supports A Cautious Buy

Dec 25, 2025, 8:30 AM EST - 2 months ago

ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts

Dec 22, 2025, 8:00 AM EST - 3 months ago

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

Nov 10, 2025, 8:00 AM EST - 4 months ago

ArriVent BioPharma Reports Third Quarter 2025 Financial Results

Sep 22, 2025, 4:05 PM EDT - 6 months ago

ArriVent Appoints Brent S. Rice as Chief Commercial Officer

Sep 9, 2025, 8:00 AM EDT - 6 months ago

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

Aug 11, 2025, 8:00 AM EDT - 7 months ago

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

Jul 21, 2025, 8:00 AM EDT - 8 months ago

ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

Jul 2, 2025, 8:22 AM EDT - 9 months ago

Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

BV CNC

Jul 1, 2025, 11:15 PM EDT - 9 months ago

ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Jul 1, 2025, 4:05 PM EDT - 9 months ago

ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Jun 23, 2025, 7:00 AM EDT - 9 months ago

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study

Jun 20, 2025, 4:05 PM EDT - 9 months ago

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

May 12, 2025, 8:00 AM EDT - 11 months ago

ArriVent BioPharma Reports First Quarter 2025 Financial Results

Apr 28, 2025, 8:00 AM EDT - 11 months ago

ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Mar 3, 2025, 7:00 AM EST - 1 year ago

ArriVent BioPharma Reports Full Year 2024 Financial Results

Jan 21, 2025, 7:00 PM EST - 1 year ago

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

Sep 9, 2024, 12:05 PM EDT - 1 year ago

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

Aug 15, 2024, 7:01 AM EDT - 1 year ago

Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma

Aug 14, 2024, 4:01 PM EDT - 1 year ago

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

Aug 12, 2024, 8:00 AM EDT - 1 year ago

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

Jun 5, 2024, 7:00 AM EDT - 1 year ago

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

May 16, 2024, 4:05 PM EDT - 1 year ago

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

May 8, 2024, 8:00 AM EDT - 2 years ago

ArriVent BioPharma Reports First Quarter 2024 Financial Results

Apr 22, 2024, 4:05 PM EDT - 2 years ago

ArriVent Appoints Kristine Peterson to its Board of Directors

Mar 28, 2024, 8:30 PM EDT - 2 years ago

InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

Mar 28, 2024, 4:05 PM EDT - 2 years ago

ArriVent BioPharma Reports Full Year 2023 Financial Results

Jan 29, 2024, 6:15 PM EST - 2 years ago

ArriVent Wows Investors With Promising China-Developed Lung Cancer Treatment

StockNews_Live Mar. 17 at 9:01 PM

0 · Reply

OfficialStocktwitsUser Mar. 16 at 4:29 PM

0 · Reply

Stackdoe101 Mar. 9 at 2:43 PM

$AVBP $OMDA $RDNW $AVXL 🙃✨

0 · Reply

elmono Mar. 6 at 10:01 AM

$AVBP event driven data delayed to mid 2026 is likely a positive for trial outcome….. if anything the balance of probabilities should cause the sp to rise …..

1 · Reply

Eagley3k Mar. 6 at 1:02 AM

$AVBP data delayed to mid 2026?

2 · Reply

StockNews_Live Mar. 5 at 9:05 PM

0 · Reply

justiceforb_85 Mar. 5 at 2:17 AM

$AVBP impressive movement.

0 · Reply

judgeyoung2 Mar. 4 at 6:11 PM

$AVBP i guess i’ll strangle it. if no data comes by tomorrow, i’ll dip.

0 · Reply

judgeyoung2 Mar. 4 at 4:17 PM

$AVBP @cubie @tonyctl anything interesting on the flow?

1 · Reply

Zawang Mar. 4 at 3:54 PM

$AVBP why is this up so much today? I can’t find any news.

0 · Reply

Eagley3k Mar. 4 at 3:32 PM

$AVBP Took a position today.

0 · Reply

QuantInsider Feb. 28 at 4:11 PM

$AVBP had a quiet week No big news, just a single OTM call sweep caught my eye 155 contracts of Mar 20 $35 calls, 47% OTM, bought at the ask for about $49.6K Looks like a speculative play, not a big bullish move Implied volatility on that call is around 246%, so options are pricey Watch out for decay unless a big move happens soon This feels more like a watchlist anomaly than a setup No strong signals here, just keeping an eye on it

0 · Reply

OfficialStocktwitsUser Feb. 27 at 2:03 AM

$AVBP RSI: 71.08, MACD: 0.3398 Vol: 0.73, MA20: 22.50, MA50: 22.05 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Quantumup Feb. 24 at 1:24 PM

Oppenheimer reiterated $ORIC Outperform/$15, and said, ORIC reported fourth quarter and full year 2025 results that support what increasingly feels like a two-shots-on-goal story. $PFE $JNJ TAK AZN NVS $AVBP $BDTX Rinzimetostat continues to look competitive in mCRPC with 55% PSA50, 20% PSA90, and 59% ctDNA clearance, and has now moved into dose optimization ahead of a planned 1H26 Phase 3 start. While Pfizer's upcoming MEVPRO-1 readout will be a pivotal moment for the PRC2 class, we believe rinzi can differentiate on safety and PK. In parallel, enozertinib's exon 20 and PACC data has demonstrated systemic activity and compelling CNS control, with the Phase 3 monotherapy dose selected and combo with subcutaneous amivantamab progressing. We will be hosting ORIC management for a fireside chat during our Healthcare Conference on Wednesday, February 25th at 12:00 PM EST. Reiterate Outperform.

0 · Reply

BillionerOfKing Feb. 19 at 4:04 PM

$AVBP Current Stock Price: $23.14 Contracts to trade: $22.5 AVBP Feb 20 2026 Call Entry: $4.37 Exit: $5.88 ROI: 34% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

SuperGreenToday Feb. 19 at 12:23 PM

$AVBP Share Price: $23.27 Contract Selected: Jul 17, 2026 $20 Calls Buy Zone: $8.34 – $10.30 Target Zone: $14.66 – $17.92 Potential Upside: 66% ROI Time to Expiration: 147 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

drose0527 Feb. 18 at 2:22 AM

$AVBP we be popping soon back to 26 $AQST ! I need people to talk to here come over to AVBP only 200 watchers

2 · Reply

drose0527 Feb. 14 at 2:34 AM

$AVBP liking the after hours run on this! Can’t believe there are only 200 ish followers in here. Pretty quiet board

0 · Reply

drose0527 Feb. 13 at 4:45 AM

$AVBP liking the set up on this one. All MA pretty much in check. Chart looks to be heading north. Bottom line showing higher lows. Anyone give me feedback on this one? Not many watchers here I’ll take a deeper dive into tomorrow but any and all feedback welcome

0 · Reply

justiceforb_85 Feb. 11 at 5:51 PM

$AVBP nervous but also excited for upcoming P3 study results for firmonertinib.

1 · Reply

QuantInsider Feb. 10 at 9:06 PM

What's up with $AVBP? Down about 4.5% this week Saw an unusual call sweep today 912 Feb 20 $25 calls, around 16% out of the money, at 138% IV That's about $91K in premium But with no news and bearish momentum, this feels like one trader taking a shot at short-term upside No broad conviction here Staying cautious until more flow or confirmation shows up

1 · Reply

judgeyoung2 Feb. 9 at 3:23 PM

$AVBP decent amount of options flow recently

0 · Reply

Market Cap	1.06B
Revenue (ttm)	0.00
Net Income (ttm)	-166.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	298,400
Avg Vol	509,552
Day's Range	N/A - N/A
Shares Out	44.20M
Stochastic %K	33%
Beta	0.99
Analysts	Strong Sell
Price Target	$42.25